Metrics as of 10/15/2026, 05:58 PM (Berlin time), refresh in progress.
CareCloud, Inc.
CareCloud, Inc. operates as a specialized healthcare technology firm, delivering a comprehensive portfolio of cloud-powered solutions and related professional services. Its primary clientele consists of medical providers and hospitals throughout the United States. The company strategically organizes its activities…
1D
+10.2%
1W
+0.5%
1M
-4.9%
6M
-36.1%
YTD
-33.2%
1Y
-38.7%
2Y
-22.0%
5Y
-74.0%
10Y
+121.6%
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~48% stronger price swings than usual
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.13
MEDIAN
US$3.13
PRICE TARGET HIGH
US$3.25
0
STRONG BUY
6
BUY
2
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 12/03/2026
P/E
27.94
P/B
4.76
EV/EBITDA
4.35
RETURN ON EQUITY
6.4%
NET MARGIN
3.5%
DEBT/EQUITY
3.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
60.0%
FLOAT SHARES
25,497,037
AVG. DAILY VOLUME (30D)
243,357
BUSQUET ANNE
KORN BILL
Sharnak Lawrence Steven
MUNTER CAMERON
MUNTER CAMERON
CareCloud, Inc. is a company in the Healthcare sector, Medical - Healthcare Information Services industry, headquartered in United States.
The CEO is Stephen A. Snyder, the company employs around 3,650 people.
The IPO was on 23/07/2014; the stock trades on NASDAQ under the ticker CCLD.
8 analysts rate the stock, the consensus is Buy (as of 12/03/2026).
The average price target is US$3.13, ranging from US$3.00 to US$3.25, with a median of US$3.13.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 48% stronger than usual.
No, CareCloud currently does not pay a dividend.
Comparable stocks include Hinge Health, HealthEquity, Heartflow, Omada Health, Teladoc Health, Evolent Health, SOPHiA GENETICS and Optima Health.
Clicking "Analyze stock" lets five strategies assess CareCloud against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.